Opinion|Videos|August 13, 2026
TONES 5 and Long-Term Durability: Does Efficacy Sustain Over Time?
Winter examines the TONES 5 randomized-withdrawal trial, discussing how sustained efficacy over 6 months factors into clinical decision-making and patient adherence in a chronic condition like EDS.
Advertisement
Episodes in this series
Winter examines the TONES 5 randomized-withdrawal trial, discussing how sustained efficacy over 6 months factors into clinical decision-making and patient adherence in a chronic condition like EDS. He emphasizes durability as a key consideration for long-term therapy success.
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
The all-oral combination is supported by phase 3 LITESPARK-011 data showing improved progression-free survival compared with cabozantinib.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5